3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
5
Thrombocytopenia
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Leukemia
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Primary Myelofibrosis
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Oligometastatic Disease
1
Oligodendroglioma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
HER2 Negative Breast Cancer
1
Glioma
1
Interventions
pirtobrutinib
6
Cyclophosphamide
6
Mycophenolic Acid
5
fludarabine phosphate
4
fludarabine
4
Rituximab
4
Melphalan
4
Azacitidine
4
venetoclax
3
ibrutinib
3
Whole-Body Irradiation
3
Tacrolimus
3
Mesna
3
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Lenalidomide
2
Cyclosporine
2
Busulfan
2
Brentuximab Vedotin
2
Bone Marrow Transplantation
2
Blood Specimen Collection
2
Bendamustine Hydrochloride
2
zanubrutinib
1
ruxolitinib
1
ponatinib
1
pembrolizumab
1
nilotinib
1
idelalisib
1
idecabtagene vicleucel
1
cedazuridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Tretinoin
×
1 year
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled